Concepts (126)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 5 | 2017 | 49 | 0.960 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2017 | 19 | 0.410 |
Why?
|
| General Surgery | 2 | 2013 | 49 | 0.400 |
Why?
|
| Aptitude Tests | 1 | 2013 | 3 | 0.400 |
Why?
|
| Genetic Therapy | 2 | 2013 | 83 | 0.390 |
Why?
|
| Skin Neoplasms | 2 | 2013 | 60 | 0.350 |
Why?
|
| Ileal Neoplasms | 1 | 2011 | 3 | 0.350 |
Why?
|
| Clinical Competence | 1 | 2013 | 191 | 0.350 |
Why?
|
| Herpesvirus 1, Human | 1 | 2010 | 2 | 0.320 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2010 | 19 | 0.320 |
Why?
|
| Genetic Vectors | 1 | 2010 | 55 | 0.310 |
Why?
|
| Laparoscopy | 1 | 2011 | 185 | 0.310 |
Why?
|
| Neoplasm Staging | 2 | 2017 | 353 | 0.290 |
Why?
|
| Rosaniline Dyes | 1 | 2008 | 2 | 0.290 |
Why?
|
| Radioisotopes | 1 | 2008 | 13 | 0.290 |
Why?
|
| Neoplasm Invasiveness | 1 | 2008 | 88 | 0.280 |
Why?
|
| Breast Neoplasms | 1 | 2008 | 376 | 0.220 |
Why?
|
| Immunotherapy | 2 | 2013 | 50 | 0.190 |
Why?
|
| Cancer Vaccines | 2 | 2012 | 7 | 0.170 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2012 | 45 | 0.170 |
Why?
|
| Humans | 13 | 2017 | 23495 | 0.140 |
Why?
|
| Sentinel Lymph Node | 1 | 2017 | 1 | 0.130 |
Why?
|
| Watchful Waiting | 1 | 2017 | 11 | 0.130 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 26 | 0.130 |
Why?
|
| Clinical Clerkship | 2 | 2013 | 26 | 0.120 |
Why?
|
| Opioid-Related Disorders | 1 | 2017 | 56 | 0.120 |
Why?
|
| Pain Management | 1 | 2017 | 132 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2017 | 378 | 0.120 |
Why?
|
| Adult | 5 | 2017 | 7090 | 0.120 |
Why?
|
| Animals | 6 | 2013 | 3321 | 0.120 |
Why?
|
| Mental Disorders | 1 | 2017 | 134 | 0.120 |
Why?
|
| Retrospective Studies | 3 | 2017 | 3082 | 0.110 |
Why?
|
| Lymph Nodes | 2 | 2017 | 71 | 0.110 |
Why?
|
| Gastroscopy | 1 | 2015 | 9 | 0.110 |
Why?
|
| Gastrostomy | 1 | 2015 | 9 | 0.110 |
Why?
|
| Analgesics, Opioid | 1 | 2017 | 215 | 0.110 |
Why?
|
| Patient Safety | 1 | 2015 | 35 | 0.110 |
Why?
|
| Middle Aged | 5 | 2017 | 8096 | 0.110 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2015 | 66 | 0.100 |
Why?
|
| Animals, Laboratory | 1 | 2013 | 3 | 0.100 |
Why?
|
| Head and Neck Neoplasms | 1 | 2015 | 138 | 0.100 |
Why?
|
| Vitiligo | 1 | 2013 | 2 | 0.100 |
Why?
|
| Hypopigmentation | 1 | 2013 | 2 | 0.100 |
Why?
|
| Mutant Proteins | 1 | 2013 | 6 | 0.100 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2013 | 5 | 0.100 |
Why?
|
| Autoimmunity | 1 | 2013 | 11 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 31 | 0.100 |
Why?
|
| Education, Medical | 1 | 2013 | 41 | 0.100 |
Why?
|
| Students, Medical | 1 | 2013 | 48 | 0.100 |
Why?
|
| Immunotherapy, Active | 1 | 2012 | 2 | 0.090 |
Why?
|
| Laparoscopes | 1 | 2011 | 2 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 197 | 0.090 |
Why?
|
| Kidney Neoplasms | 1 | 2012 | 75 | 0.080 |
Why?
|
| Biopsy, Needle | 1 | 2011 | 101 | 0.080 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 340 | 0.080 |
Why?
|
| Defective Viruses | 1 | 2010 | 1 | 0.080 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2010 | 2 | 0.080 |
Why?
|
| Injections, Intralesional | 1 | 2010 | 28 | 0.080 |
Why?
|
| Clinical Protocols | 1 | 2010 | 53 | 0.080 |
Why?
|
| Virus Replication | 1 | 2010 | 43 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2015 | 3058 | 0.080 |
Why?
|
| Male | 6 | 2017 | 12823 | 0.080 |
Why?
|
| Mice | 2 | 2013 | 1264 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2013 | 1528 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 2010 | 92 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2010 | 135 | 0.080 |
Why?
|
| Patient Selection | 1 | 2010 | 171 | 0.070 |
Why?
|
| Research Design | 1 | 2010 | 165 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2010 | 107 | 0.070 |
Why?
|
| Drug Hypersensitivity | 1 | 2008 | 6 | 0.070 |
Why?
|
| Coloring Agents | 1 | 2008 | 14 | 0.070 |
Why?
|
| Aged | 4 | 2017 | 7709 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 126 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 594 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2008 | 228 | 0.070 |
Why?
|
| Linear Models | 1 | 2008 | 203 | 0.070 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2011 | 295 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 1492 | 0.060 |
Why?
|
| Female | 5 | 2017 | 13305 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 449 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2008 | 552 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2008 | 1500 | 0.050 |
Why?
|
| Young Adult | 2 | 2017 | 1724 | 0.050 |
Why?
|
| Vaccines, DNA | 2 | 2012 | 6 | 0.040 |
Why?
|
| Postoperative Complications | 2 | 2017 | 827 | 0.040 |
Why?
|
| Clinical Trials as Topic | 2 | 2012 | 192 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 3874 | 0.030 |
Why?
|
| Pain Clinics | 1 | 2017 | 4 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 3 | 0.030 |
Why?
|
| Lymphedema | 1 | 2017 | 4 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 315 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 85 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 171 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 227 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 124 | 0.030 |
Why?
|
| Palliative Care | 1 | 2017 | 108 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 280 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2017 | 207 | 0.030 |
Why?
|
| Prognosis | 1 | 2017 | 737 | 0.030 |
Why?
|
| Antigens | 1 | 2013 | 9 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2013 | 8 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2013 | 43 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 102 | 0.020 |
Why?
|
| Forecasting | 1 | 2013 | 80 | 0.020 |
Why?
|
| Vaccination | 1 | 2013 | 26 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2013 | 28 | 0.020 |
Why?
|
| Transfection | 1 | 2013 | 115 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2013 | 118 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2013 | 95 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2013 | 76 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 139 | 0.020 |
Why?
|
| Disease Management | 1 | 2013 | 98 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 93 | 0.020 |
Why?
|
| Anxiety | 1 | 2013 | 143 | 0.020 |
Why?
|
| Peptides | 1 | 2013 | 89 | 0.020 |
Why?
|
| Skin | 1 | 2013 | 113 | 0.020 |
Why?
|
| Phenotype | 1 | 2013 | 260 | 0.020 |
Why?
|
| Models, Immunological | 1 | 2012 | 4 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 26 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 368 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2013 | 215 | 0.020 |
Why?
|
| Inflammation | 1 | 2013 | 236 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 550 | 0.020 |
Why?
|
| Models, Animal | 1 | 2010 | 103 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 1045 | 0.020 |
Why?
|
| United States | 1 | 2013 | 1814 | 0.020 |
Why?
|